Fulgent Genetics
FLGT

Fulgent Genetics (FLGT) earnings history

Most recent quarter

Period end
Jun 30, 2026
EPS actual
−$0.58
EPS estimate
−$0.46
EPS surprise
−26.09%
Revenue
$85.4M
Reported
Jul 30, 2026

Earnings history

PeriodReportedEPS estimateEPS actualSurpriseRevenueFiling
Q2 2026Jul 30, 2026−$0.46−$0.58−26.09%$85.4MSEC
Q1 2026May 1, 2026−$0.35−$0.36−3.39%$71.1MSEC
Q4 2025Feb 27, 2026$0.03$0.16+436.91%$83.3MSEC
Q3 2025Nov 7, 2025−$0.22$0.14+162.44%$84.1MSEC
Q2 2025Aug 1, 2025−$0.18$0.07+137.88%$81.8MSEC
Q1 2025May 2, 2025−$0.18$0.04+122.30%$73.5MSEC
Q4 2024Feb 28, 2025−$0.12$0.04+132.60%$76.2MSEC
Q3 2024Nov 8, 2024−$0.15$0.31+301.56%$71.7MSEC
Q2 2024Aug 2, 2024−$0.30$0.15+150.22%$71.0MSEC
Q1 2024May 3, 2024−$0.32−$0.01+96.86%$64.5MSEC

Quarterly revenue

Q1 2024
$64.5M
Q2 2024
$71.0M
Q3 2024
$71.7M
Q4 2024
$76.2M
Q1 2025
$73.5M
Q2 2025
$81.8M
Q3 2025
$84.1M
Q4 2025
$83.3M
Q1 2026
$71.1M
Q2 2026
$85.4M

Frequently asked questions

  • When did Fulgent Genetics (FLGT) last report earnings?

    Fulgent Genetics last reported on Jul 30, 2026, covering fiscal Q2 2026.

  • Did FLGT beat earnings estimates?

    No. Fulgent Genetics reported EPS of −$0.58 for Q2 2026 against a −$0.46 estimate — a 26.09% miss.

  • How much revenue did FLGT report last quarter?

    Fulgent Genetics reported $85.4M in revenue for Q2 2026, against a consensus estimate of $94.0M.

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.